4-(5-benzylbenzofuran-2-yl)-3-fluorobenzaldehyde | 939050-33-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: 4-(5-benzylbenzofuran-2-yl)-3-fluorobenzaldehyde
• 英文别名: 4-(5-benzyl-1-benzofuran-2-yl)-3-fluorobenzaldehyde
• CAS: 939050-33-6
• 化学式: C₂₂H₁₅FO₂
• 分子量: 330.358
• InChiKey: ZNHIJNTUGVMVFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-benzylbenzofuran-2-yl)-3-fluorobenzaldehyde 、 3-吖丁啶羧酸 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以56%的产率得到1-((4-(5-benzylbenzofuran-2-yl)-3-fluorophenyl)methyl)azetidine-3-carboxylic acid
  参考文献：
  名称：

  Benzofuran Derivatives as Potent, Orally Active S1P₁ Receptor Agonists: A Preclinical Lead Molecule for MS

  摘要：

  We have discovered novel benzofuran-based S1P(1) agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P(1) agonist with > 1000 x selectivity over S1P(3). It demonstrated a good in vitro ADME profile and excellent oral bioavailability across species. Dosed orally at 0.3 mg/kg, 18 significantly reduced blood lymphocyte counts 24 h postdose and demonstrated efficacy in a mouse EAE model of relapsing MS.

  DOI：

  10.1021/ml100227q
• 作为产物：
  描述：

  4-羟基二苯甲烷 在 bis-triphenylphosphine-palladium(II) chloride 、 正丁基锂 、 硼酸三异丙酯 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二甲基亚砜 、 苯 为溶剂， 反应 20.0h， 生成 4-(5-benzylbenzofuran-2-yl)-3-fluorobenzaldehyde
  参考文献：
  名称：

  Benzofuran Derivatives as Potent, Orally Active S1P₁ Receptor Agonists: A Preclinical Lead Molecule for MS

  摘要：

  We have discovered novel benzofuran-based S1P(1) agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P(1) agonist with > 1000 x selectivity over S1P(3). It demonstrated a good in vitro ADME profile and excellent oral bioavailability across species. Dosed orally at 0.3 mg/kg, 18 significantly reduced blood lymphocyte counts 24 h postdose and demonstrated efficacy in a mouse EAE model of relapsing MS.

  DOI：

  10.1021/ml100227q

文献信息

• S1P receptor modulating compounds and use thereof
  申请人：Saha Ashis K.

  公开号：US20080064677A9

  公开（公告）日：2008-03-13

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其作为S1P受体调节剂具有活性，并使用这种化合物来治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、炎症性肠病（如克罗恩病和溃疡性结肠炎）、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behcet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Saha Ashis K.

  公开号：US20110059945A1

  公开（公告）日：2011-03-10

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其具有作为S1P受体调节剂的活性，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、克罗恩病和溃疡性结肠炎、I型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• Direct α-Arylation of Benzo[<i>b</i>]furans Catalyzed by a Pd₃ Cluster
  作者：Jian Yao、Lili Shao、Xi Kang、Manzhou Zhu、Xiaohong Huo、Xiaoming Wang

  DOI：10.1021/acs.joc.3c02428

  日期：2024.2.2

  organic transformations and mechanistic investigations is still largely unexploited. Herein, we disclose the use of trinuclear palladium (Pd3Cl) species as an active catalyst for the direct C–H α-arylation of benzo[b]furans with aryl iodides to afford 2-arylbenzofurans in good yields under mild conditions. With this method, broad substrate adaptability was observed, and several drug intermediates were

  作为基于更传统的单核分子 Pd 配合物和广泛用于有机合成的 Pd n纳米粒子的催化剂之间的过渡范例，多核钯簇因其独特的反应性和电子特性而引起了极大的关注。然而，用于有机转化和机理研究的钯簇催化剂的开发在很大程度上仍未得到开发。在此，我们公开了使用三核钯（Pd 3 Cl）物质作为活性催化剂，用于苯并[ b ]呋喃与芳基碘化物的直接C-H α-芳基化，在温和条件下以良好的产率提供2-芳基苯并呋喃。利用该方法，观察到了广泛的底物适应性，并以高产率合成了多种药物中间体。机理研究表明，Pd 3核心很可能在整个反应过程中保持完整。
• S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF
  申请人：EPIX Pharmaceuticals, Inc.

  公开号：EP2121648A2

  公开（公告）日：2009-11-25
• US7855193B2
  申请人：——

  公开号：US7855193B2

  公开（公告）日：2010-12-21